Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement

Sep 11 2013

• By Sarah Karlin-Smith

Related Content

Forest <em>Tudorza</em> <em>Pressair</em> Approval For COPD Includes Post-marketing CV Safety Study

Jul 23 2012

Advair Bioequivalence Guidance Falls Short of GSK’s Requests

Sep 10 2013

GSK’s <em>Breo Ellipta</em> Approved With COPD Airflow Obstruction, Exacerbation Claims

May 10 2013

Related Companies

GSK plc

Innoviva, Inc.

Additional Topics

United States Clinical Trials Regulation Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window